Targetting esophageal and gastric cancers with monoclonal antibodies

Current Topics in Medicinal Chemistry

Volumn 12, Issue 15, 2012, Pages 1678-1682

  Norguet, Emmanuelle ^a   Dahan, Laetitia ^a   Seitz, Jean François ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Esophageal cancer; Gastric cancer; Gastroesophageal cancer; Monoclonal antibodies; Target therapies

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1; IRINOTECAN; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAMUCIRUMAB; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL JUNCTION CANCER; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; NAUSEA; NEUTROPENIA; STOMACH ADENOCARCINOMA; STOMACH CANCER; WOUND HEALING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS;

EID: 84867566274     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803531360     Document Type: Article

References (38)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBO- CAN 2008. Int. J. Cancer, 2010, 127, 2893-2917.
2. Goldstein, N.I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1995, 1, 1311-1318.
3. Merck. Preclinical report AB 01.2004. Binding competition between C225 and different epidermal growth factor ligands. November 26, 2003.
4. Li, S.; Schmitz, K.R.; Jeffrey, P.D.; Wiltzius, J.J.; Kussie, P.; Ferguson, K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell, 2005, 7, 301-311.
5. Waksal, H.W. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev., 1999, 18, 427-436.
6. Hadari, Y.R.; Doody, J.F.; Wang, Y.; Patel, S.N.; Apblett, R.L.; Loizos, N.; Pereira, D.S.; Witte, L.; Bohlen, P.; Hicklin, D.J.; Kussie, P. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor. ASCO Gastrointestinal Cancers Symposium, 2004, Abstract 234.
7. Zhang, W.; Gordon, M.; Schultheis, A.M.; Nagashima, F.; Azuma, M.; Yang, D.; Iqbal, S.; Lenz, H. Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab. J. Clin. Oncol., 2006, 24(18S), Abstract 3028.
8. Kimura, H.; Sakai, K.; Arao, T.; Shimoyama, T.; Takeda, M.; Kasahara, K.; Nishio, K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild- and mutant-EGFR. Proc. Amer. Assoc. Cancer Res., 2006, 47, Abstract 636.
9. Gibault, L.; Metges, J.P.; Conan-Charlet, V.; Lozac'h, P.; Robaszkiewicz, M.; Bessaguet, C.; Lagarde, N.; Volant, A. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br. J. Cancer, 2005, 93, 107-115.
10. Wei, Q.; Chen, L.; Sheng, L.; Nordgren, H.; Wester, K.; Carlsson, J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int. J. Oncol., 2007, 31, 493-499.
11. Langer, R.; Von Rahden, B.H.; Nahrig, J.; Von Weyhern, C.; Reiter, R.; Feith, M.; Stein, H.J.; Siewert, J.R.; Höfler, H.; Sarbia, M. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J. Clin. Pathol., 2006, 59, 631-634.
12. Rao, S.; Starling, N.; Cunningham, D.; Sumpter, K.; Gilligan, D.; Ruhstaller, T.; Valladares-Ayerbes, M.; Wilke, H.; Archer, C.; Kurek, R.; Beadman, C.; Oates, J. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann. Oncol., 2010, 21, 2213-2219.
13. Gravalos, C.; Jimeno, A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol., 2008, 19, 1523-1529.
14. Okines, A.F.; Reynolds, A.R.; Cunningham, D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist, 2011, 16, 844-858.
15. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M.S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E.K.; Ang, K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 2006, 354, 567-578.
16. Safran, H.; Suntharalingam, M.; Dipetrillo, T.; Ng, T.; Doyle, L.A.; Krasna, M.; Plette, A.; Evans, D.; Wanebo, H.; Akerman, P.; Spector, J.; Kennedy, N.; Kennedy, T. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int. J. Radiat. Oncol. Biol. Phys., 2008, 70, 391-395.
17. De Vita, F.; Orditura, M.; Martinelli, E.; Vecchione, L.; Innocenti, R.; Sileni, V.C.; Pinto, C.; Di Maio, M.; Farella, A.; Troiani, T.; Morgillo, F.; Napolitano, V.; Ancona, E.; Di Martino, N.; Ruol, A.; Galizia, G.; Del Genio, A.; Ciardiello, F. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br. J. Cancer, 2011, 104, 427-432.
18. Ruhstaller, T.; Pless, M.; Dietrich, D.; Kranzbuehler, H.; von Moos, R.; Moosmann, P.; Montemurro, M.; Schneider, P.M.; Rauch, D.; Gautschi, O.; Mingrone, W.; Widmer, L.; Inauen, R.; Brauchli, P.; Hess, V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J. Clin. Oncol., 2011, 29, 626-631.
19. Lledo, G.; Michel, P.; Dahan, L.; Mineur, L.; Galais, M.; Dupuis, O.; Abdiche, S.; Jovenin, N.; Chibaudel, B.; De Gramont, A. Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX). J. Clin. Oncol., 2011, 29(4), Abstract 8.
20. Lorenzen, S.; Schuster, T.; Porschen, R.; Al-Batran, S.E.; Hofheinz, R.; Thuss-Patience, P.; Moehler, M.; Grabowski, P.; Arnold, D.; Greten, T.; Müller, L.; Röthling, N.; Peschel, C.; Langer, R.; Lordick, F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann. Oncol., 2009, 20, 1667-1673.
21. Gold, P.J.; Goldman, B.; Iqbal, S.; Leichman, L.P.; Zhang, W.; Lenz, H.J.; Blanke, C.D. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J. Thorac. Oncol., 2010, 5, 1472-1476.
22. Kim, S.E.; Shim, K.N.; Jung, S.A.; Yoo, K.; Lee, J.H. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut. Liver, 2009, 3, 88-94.
23. Lieto, E.; Ferraraccio, F.; Orditura, M.; Castellano, P.; Mura, A.L.; Pinto, M.; Zamboli, A.; De Vita, F.; Galizia, G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann. Surg. Oncol., 2008, 15, 69-79.
24. Maeda, K.; Chung, Y.S.; Ogawa, Y.; Takatsuka, S.; Kang, S.M.; Ogawa, M.; Sawada, T.; Sowa, M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer, 1996, 77, 858-863.
25. Song, Z.J.; Gong, P.; Wu, Y.E. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J. Gastroenterol., 2002, 8, 591-595.
26. Shah, M.A.; Ramanathan, R.K.; Ilson, D.H.; Levnor, A.; D'Adamo, D.; O'Reilly, E.; Tse, A.; Trocola, R.; Schwartz, L.; Capanu, M.; Schwartz, G.K.; Kelsen, D.P. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol., 2006, 24, 5201-5206.
27. El-Rayes, B.F.; Zalupski, M.; Bekai-Saab, T.; Heilbrun, L.K.; Hammad, N.; Patel, B.; Urba, S.; Shields, A.F.; Vaishampayan, U.; Dawson, S.; Almhanna, K.; Smith, D.; Philip, P.A. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann. Oncol., 2010, 21, 1999-2004.
28. Shah, M.A.; Jhawer, M.; Ilson, D.H.; Lefkowitz, R.A.; Robinson, E.; Capanu, M.; Kelsen, D.P. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J. Clin. Oncol., 2011, 29, 868-874.
29. Ohtsu, A.; Shah, M.A.; Van Cutsem, E.; Rha, S.Y.; Sawaki, A.; Park, S.R.; Lim, H.Y.; Yamada, Y.; Wu, J.; Langer, B.; Starnawski, M.; Kang, Y.K. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol., 2011, 29, 3968-3976.
30. Pinto, C.; Di Fabio, F.; Barone, C.; Siena, S.; Falcone, A.; Cascinu, S.; Rojas Llimpe, F.L.; Stella, G.; Schinzari, G.; Artale, S.; Mutri, V.; Giaquinta, S.; Giannetta, L.; Bardelli, A.; Martoni, A.A. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br. J. Cancer, 2009, 101, 1261-1268.
31. Lordick, F.; Luber, B.; Lorenzen, S.; Hegewisch-Becker, S.; Folprecht, G.; Wöll, E.; Decker, T.; Endlicher, E.; Röthling, N.; Schuster, T.; Keller, G.; Fend, F.; Peschel, C. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br. J. Cancer, 2010, 102, 500-505.
32. Han, S.W.; Oh, D.Y.; Im, S.A.; Park, S.R.; Lee, K.W.; Song, H.S.; Lee, N.S.; Lee, K.H.; Choi, I.S.; Lee, M.H.; Kim, M.A.; Kim, W.H.; Bang, Y.J.; Kim, T.Y. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br. J. Cancer, 2009, 100, 298-304.
33. Schoennemann, K.R.; Bjerregaard, J.K.; Hansen, T.P.; De Stricker, K.; Gjerstorff, M.F.; Jensen, H.A.; Vestermark, L.W.; Pfeiffer, P. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer, 2011, 14, 219-225.
34. Kim, C.; Lee, J.L.; Ryu, M.H.; Chang, H.M.; Kim, T.W.; Lim, H.Y.; Kang, H.J.; Park, Y.S.; Ryoo, B.Y.; Kang, Y.K. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest. New Drugs, 2011, 29, 366-373.
35. Chan, J.A.; Blaszkowsky, L.S.; Enzinger, P.C.; Ryan, D.P.; Abrams, T.A.; Zhu, A.X.; Temel, J.S.; Schrag, D.; Bhargava, P.; Meyerhardt, J.A.; Wolpin, B.M.; Fidias, P.; Zheng, H.; Florio, S.; Regan, E.; Fuchs, C.S. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann. Oncol., 2011, 22, 1367-1373.
36. Pinto, C.; Di Fabio, F.; Siena, S.; Cascinu, S.; Rojas Llimpe, F.L.; Ceccarelli, C.; Mutri, V.; Giannetta, L.; Giaquinta, S.; Funaioli, C.; Berardi, R.; Longobardi, C.; Piana, E.; Martoni, A.A. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann. Oncol., 2007, 18, 510-517.
37. Okines, A.F.; Ashley, S.E.; Cunningham, D.; Oates, J.; Turner, A.; Webb, J.; Saffery, C.; Chua, Y.J.; Chau, I. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J. Clin. Oncol., 2010, 28, 3945-3950.
38. Bang, Y.J.; Van Cutsem, E.; Feyereislova, A.; Chung, H.C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.; Omuro, Y.; Satoh, T.; Aprile, G.; Kulikov, E.; Hill, J.; Lehle, M.; Rüschoff, J.; Kang, Y.K.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376, 687-697.